Clément Bonnet1, Pascaline Boudou-Rouquette1, Esther Azoulay-Rutman2, Olivier Huillard1, Jean-Louis Golmard3, Edith Carton1, Gaëlle Noé2, Michel Vidal2,4, Galdric Orvoen5, Anne Chah Wakilian5, Clémentine Villeminey1, Benoit Blanchet2, Jérôme Alexandre1, François Goldwasser1, Audrey Thomas-Schoemann6,7. 1. Assistance publique des Hôpitaux de Paris, Service de Cancérologie médicale, Hôpital Cochin, Paris, France. 2. Assistance publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France. 3. Assistance publique des Hôpitaux de Paris, Département de Biostatistiques, Hôpital Pitié- Salpétrière, Paris, France. 4. UMR8638 CNRS, UFR De Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France. 5. Service de Gériatrie, Hôpital Broca, Hôpitaux Paris Centre, Université Paris Descartes, Paris, France. 6. Assistance publique des Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, Paris, France. schoemann.audrey@gmail.com. 7. UMR8638 CNRS, UFR De Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France. schoemann.audrey@gmail.com.
Abstract
PURPOSE: Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent may result in drug-drug interactions (DDI). We aimed to evaluate the prevalence of DDI with abiraterone and the possible determinants for the occurrence of these DDI. METHODS: We performed a single centre retrospective review from electronic medical records of mCRPC patients treated with abiraterone from 2011 to 2015. Potential DDI with abiraterone were identified using Micromedex and were categorized by a 4-point scale severity. RESULTS: Seventy-two out of ninety-five mCRPC pts (median age: 77 years [68-82]) had comorbidities. The median number of drugs used per patient was 7 [5-9]. 66 potential DDI with abiraterone were detected in 49 patients (52%): 39 and 61% were classified as major and moderate DDI, respectively. In the univariate analysis, pain (p < 0.0001), hypo-albuminemia (p = 0.032), and higher ECOG performance status (PS) (p = 0.013) were significantly associated with a higher risk of DDI with abiraterone. Pain (p < 0.0001) and PS (p = 0.018) remained significant in the multivariate analysis. CONCLUSIONS: Polypharmacy is an issue among mCRPC patients. In our study, half of the patients have potential DDI with abiraterone. Patients with pain and poor PS are at higher risk of DDI with abiraterone. A medication review by a pharmacist is of crucial importance to prevent DDI with abiraterone.
PURPOSE:Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent may result in drug-drug interactions (DDI). We aimed to evaluate the prevalence of DDI with abiraterone and the possible determinants for the occurrence of these DDI. METHODS: We performed a single centre retrospective review from electronic medical records of mCRPC patients treated with abiraterone from 2011 to 2015. Potential DDI with abiraterone were identified using Micromedex and were categorized by a 4-point scale severity. RESULTS: Seventy-two out of ninety-five mCRPC pts (median age: 77 years [68-82]) had comorbidities. The median number of drugs used per patient was 7 [5-9]. 66 potential DDI with abiraterone were detected in 49 patients (52%): 39 and 61% were classified as major and moderate DDI, respectively. In the univariate analysis, pain (p < 0.0001), hypo-albuminemia (p = 0.032), and higher ECOG performance status (PS) (p = 0.013) were significantly associated with a higher risk of DDI with abiraterone. Pain (p < 0.0001) and PS (p = 0.018) remained significant in the multivariate analysis. CONCLUSIONS: Polypharmacy is an issue among mCRPC patients. In our study, half of the patients have potential DDI with abiraterone. Patients with pain and poor PS are at higher risk of DDI with abiraterone. A medication review by a pharmacist is of crucial importance to prevent DDI with abiraterone.
Entities:
Keywords:
Abiraterone; Drug–drug interactions; Pharmacist; Prevalence; Prostate cancer
Authors: Guillemette E Benoist; Maarten J van der Doelen; Rob Ter Heine; Nielka P van Erp; Niven Mehra Journal: Br J Clin Pharmacol Date: 2018-02-21 Impact factor: 4.335
Authors: Guillemette Emma Benoist; Inge M van Oort; Stella Smeenk; Adrian Javad; Diederik M Somford; David M Burger; Niven Mehra; Nielka P van Erp Journal: Br J Clin Pharmacol Date: 2017-10-18 Impact factor: 4.335
Authors: Katja Schlichtig; Lisa Cuba; Pauline Dürr; Laura Bellut; Norbert Meidenbauer; Frank Kunath; Peter J Goebell; Andreas Mackensen; Frank Dörje; Martin F Fromm; Bernd Wullich Journal: J Clin Med Date: 2022-08-04 Impact factor: 4.964